- Home
- RSF vs MCRB Comparison
RSF vs MCRB Comparison
Compare RSF & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RSF | MCRB |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 47.4M |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RSF | MCRB |
|---|---|---|
| Price | $14.52 | $5.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 6.7K | ★ 55.5K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.23 | $4.32 |
| 52 Week High | $15.07 | $29.98 |
Technical Indicators
Market Signals| Indicator | RSF | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 48.98 | 58.96 |
| Support Level | $14.51 | $5.31 |
| Resistance Level | $14.65 | $5.65 |
| Average True Range (ATR) | 0.04 | 0.33 |
| MACD | 0.00 | 0.16 |
| Stochastic Oscillator | 64.05 | 77.14 |
Price Performance
Historical ComparisonAbout RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.